Abattis Provides Corporate Updates

World News: . []

VANCOUVER, British Columbia, July 11, 2018 (GLOBE NEWSWIRE) -- (the "" or "") (CSE:ATT) (OTC:ATTBF) is pleased to provide the following corporate updates.

Abattis has completed a non-brokered private placement for gross proceeds of $2.25 million (the “”) through the issuance of 13,235,294 common shares of the Company priced at $0.17 per share. The Company anticipates that the Proceeds will be used to organically grow its existing downstream service division and for general working capital purposes.

Abattis’s new communications program will be managed through the following:

The Company anticipates that the new communications framework will significantly decrease the turnaround time for shareholder and general inquiries.

Abattis is a leading diversified cannabis company, with interests in operations engaged in growing, extraction, testing, propagation and retail distribution. Over the past few years, Abattis has made key acquisitions to leverage synergies and vertically integrate its business. Through Abattis’s ownership interest in Northern Vine Labs, Abattis has access to a laboratory facility holding a Health Canada dealer’s license and, through its wholly owned subsidiary Gabriola Green Farms, it has applied for a Health Canada license to produce and sell Cannabis flower and oils. Abattis also operates a retail vaporizers business through its wholly owned subsidiary, Green Tree Therapeutics, which offers 10 unique branded SKUs online and across the country and owns a series of marketing, licensing and technology rights. Abattis has also partnered with a number of organizations, including the University of British Columbia Faculty of Land and Food Systems, with which it is developing delivery platforms with increased stability and bioavailability for cannabinoid rich THC-free hemp extracts.

ON BEHALF OF THE BOARD OFABATTIS BIOCEUTICALS CORP.,

For more information, please visit the Company's website at: www.abattis.com or www.northernvinelabs.com

For inquiries, please contact the Company at (604) 674-8232 or at news@abattis.com.

 

More news and information about Abattis Bioceuticals Corp.

Published By:

Globe Newswire: 14:54 GMT Wednesday 11th July 2018

Published: .

Search for other references to "abattis" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers